Hepatotoxicity of Small Molecule Protein Kinase Inhibitors for Cancer

Area of Science:

• Oncology
• Pharmacology
• Hepatology

Background:

• Small molecule protein kinase inhibitors (PKIs) are vital in cancer therapy.
• Hepatotoxicity, indicated by elevated transaminases, is a significant safety concern with PKIs.
• Few PKIs carry boxed warnings for liver injury, and incidence rates are not well-defined.

Purpose of the Study:

• To review current data on the risks and management of hepatotoxicity associated with approved PKIs.
• To highlight the need for careful patient evaluation and monitoring during PKI therapy.

Main Methods:

• Systematic review of available literature on PKI-induced hepatotoxicity.
• Analysis of data from pre-registration, registration, and post-marketing studies.
• Examination of real-world practice studies regarding drug-related hepatotoxicity.

Main Results:

• Most PKIs can increase transaminases, with some having specific warnings.
• Hepatotoxicity data is often limited by trial selection and reporting biases.
• Hepatotoxicity is generally reversible with dose adjustments or treatment changes, and fatalities are rare.

Conclusions:

• All patients on PKIs require thorough pre-treatment evaluation and ongoing monitoring for hepatotoxicity.
• Management involves a personalized risk/benefit assessment, especially for patients responding to therapy.
• This review consolidates information on PKI hepatotoxicity to guide clinical practice.